BIONTECH SE - AMERICAN DEPOSITARY SHARES

BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update

06 Nov 2023 06:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19

26 Oct 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advanced Solid Tumors at ESMO Congress 2023

23 Oct 2023 11:30:00 By Nasdaq GlobeNewswire

BioNTech to Report Third Quarter Financial Results and Corporate Update on November 6, 2023, And to Host Innovation Series Day on November 7, 2023

23 Oct 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

19 Oct 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech to Present Multiple Program Updates Across Modalities at ESMO Congress 2023

16 Oct 2023 03:30:00 By Nasdaq GlobeNewswire

Update Regarding Pfizer’s Statement on COMIRNATY-Related Write-Offs

16 Oct 2023 03:00:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine

28 Sep 2023 12:24:00 By Nasdaq GlobeNewswire

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

18 Sep 2023 06:45:00 By Nasdaq GlobeNewswire

Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron XBB.1.5-adapted COVID-19 Vaccine in the European Union

30 Aug 2023 10:00:00 By Nasdaq GlobeNewswire

BioNTech Expands Management Board by Appointing James Ryan as Chief Legal Officer

14 Aug 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update

07 Aug 2023 06:00:00 By Nasdaq GlobeNewswire

BioNTech Completes Acquisition of InstaDeep

31 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

BioNTech and OncoC4 Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

29 Jun 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO

02 Jun 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech Announces First Quarter 2023 Financial Results and Corporate Update

08 May 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023

24 Apr 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors

03 Apr 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech Announces New ADS Repurchase Program

28 Mar 2023 06:45:00 By Nasdaq GlobeNewswire

BioNTech Announces Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

27 Mar 2023 06:45:00 By Nasdaq GlobeNewswire